C12N 2320/51
Modulating the chemical stability
Official title: modulating the chemical stability, e.g. nuclease-resistance
C12N2320/51 (Modulating the chemical stability) appears on 469 US grants and 839 published applications in this corpus.
Search patents in C12N- Granted patents
- 469
- Published applications
- 839
- Assignees
- 236
- Inventors
- 889
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 6 |
| 2004 | 1 | 18 |
| 2005 | 0 | 26 |
| 2006 | 2 | 28 |
| 2007 | 0 | 43 |
| 2008 | 3 | 12 |
| 2009 | 6 | 51 |
| 2010 | 13 | 40 |
| 2011 | 26 | 39 |
| 2012 | 28 | 29 |
| 2013 | 23 | 32 |
| 2014 | 32 | 37 |
| 2015 | 38 | 58 |
| 2016 | 26 | 52 |
| 2017 | 43 | 54 |
| 2018 | 45 | 51 |
| 2019 | 36 | 45 |
| 2020 | 32 | 36 |
| 2021 | 30 | 33 |
| 2022 | 30 | 43 |
| 2023 | 15 | 37 |
| 2024 | 15 | 25 |
| 2025 | 16 | 27 |
| 2026 | 7 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modified guide RNAs15 Sep 2026US 12,735,698 B2Intellia Therapeutics, Inc.
- Dual guide CRISPR hybrid DNA/RNA polynucleotides and methods of use2 Jun 2026US 12,644,138 B2Caribou Biosciences, Inc.
- Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof28 Apr 2026US 12,611,462 B2City of Hope
- Linkage modified oligomeric compounds and uses thereof7 Apr 2026US 12,595,482 B2Ionis Pharmaceuticals, Inc.
- Compositions and methods for treatment and prevention of Alzheimer's disease24 Mar 2026US 12,583,920 B2The General Hospital Corporation
- Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof17 Sep 2026US 2026/0273070 A1City of Hope
- Compositions, Methods, And Systems For Targeting And Destabilizing RNA Transcripts (TNBC)3 Sep 2026US 2026/0256824 A1UTR Therapeutics Inc.
- Modification of small rnas for therapeutic uses3 Sep 2026US 2026/0258415 A1City of Hope
- Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use Thereof27 Aug 2026US 2026/0248964 A1Intellia Therapeutics, Inc.
- Chemically Modified saRNA Compositions and Methods of Use30 Jul 2026US 2026/0218178 A1Mina Therapeutics Limited
Most cited
By later US patents
- In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom267US 5,624,803 AThe Regents of the University of California · 1997
- Oligonucleotides with alternating segments of locked and non-locked nucleotides183US 7,687,617 B2Santaris Pharma A/S · 2010
- Modified siRNA molecules and uses thereof167US 8,101,741 B2Protiva Biotherapeutics, Inc. · 2012
- Methods and compositions for enhancing the efficacy and specificity of RNA silencing158US 7,750,144 B2University of Massachusetts · 2010
- Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation158US 8,124,745 B2Isis Pharmaceuticals, Inc. · 2012